The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol.
We have studied the molecular effects of a LFD in a murine model in order to better define the biochemical changes associated with folate deficiency. In addition, we have demonstrated the effect of a LFD on the pharmacokinetic profile and therapeutic activity and toxicity of lometrexol. These studies showed increased density of FR in tumors implanted in LFD mice and a decrease in the affinity of these receptors for folic acid. The results suggest that tumors can compensate for low folate bioavailability by up-regulation of a second FR with slightly lower affinity for folic acid. The higher density of this FR would provide greater capacity for garnering serum folate. FPGS activity increased in several tumors and liver and kidney of LFD mice. The increase in this enzyme activity would result in enhanced polyglutamation of folates and classical antifolates and thus increased cellular retention. Consistent with these changes in liver FPGS, mice injected i.v. with a single dose of lometrexol accumulated significantly more drug in liver and tumors of LFD animals compared to SD mice. Also, higher liver concentrations of lometrexol persisted longer in LFD mice. Polyglutamate analysis showed that longer polyglutamate forms appeared earlier in liver of LFD mice. After 7 days, longer polyglutamyl forms were recovered from liver of LFD mice (octa- and hepta-glutamyl lometrexol) compared to those on SD. A comparison of the efficacy and toxicity of lometrexol in C3H mammary tumor-bearing mice showed that in mice on LFD, lometrexol treatment produced a delayed toxicity with an LD50 of 0.1-0.3 mg/kg, a 3000-fold increase in lethality compared to SD mice. Supplementation of mice with folic acid restored anti-tumor activity and increased the therapeutic dose-range over which efficacy could be assessed. These studies support the use of folic acid supplementation for cancer patients treated with antifolate therapy in order to prevent the biochemical changes in FR and FPGS associated with folate deficiency, prevent delayed toxicity to GARFT inhibitors and enhance the therapeutic potential of this class of drugs.
Mendelsohn
L G
LG
Cancer Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA.
Gates
S B
SB
Habeck
L L
LL
Shackelford
K A
KA
Worzalla
J
J
Shih
C
C
Grindey
G B
GB
D000217:Acyltransferases / Q000378:metabolism; D000818:Animals; D002352:Carrier Proteins / Q000187:drug effects / Q000378:metabolism*; D004032:Diet; D004791:Enzyme Inhibitors / Q000494:pharmacology; D058973:Folate Receptors, GPI-Anchored; D005492:Folic Acid / Q000378:metabolism / Q000494:pharmacology; D019877:Hydroxymethyl and Formyl Transferases; D007668:Kidney / Q000737:chemistry / Q000378:metabolism; D008099:Liver / Q000737:chemistry / Q000378:metabolism; D051379:Mice; D009369:Neoplasms / Q000201:enzymology; D010453:Peptide Synthases / Q000378:metabolism*; D051026:Phosphoribosylglycinamide Formyltransferase; D011099:Polyglutamic Acid / Q000378:metabolism; D011485:Protein Binding; D011956:Receptors, Cell Surface; D013763:Tetrahydrofolates / Q000378:metabolism* / Q000633:toxicity*; D014407:Tumor Cells, Cultured
D002352:Carrier Proteins; D004791:Enzyme Inhibitors; D058973:Folate Receptors, GPI-Anchored; D011956:Receptors, Cell Surface; D013763:Tetrahydrofolates; D011099:Polyglutamic Acid; C045894:lometrexol; D005492:Folic Acid; D019877:Hydroxymethyl and Formyl Transferases; D051026:Phosphoribosylglycinamide Formyltransferase; D000217:Acyltransferases; D010453:Peptide Synthases; C023103:folylpolyglutamate synthetase; C005984:5-methyltetrahydrofolate